India, April 12 -- GSK plc (GSK,GSK.L) announced encouraging findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. At the highest doses evaluated, Mo-Rez monotherapy achieved confirmed objective response rates of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).
Currently, treatment options for patients with PROC and advanced EC are limited, with modest response rates. B7-H4, an immune checkpoint widely expressed in ovarian and endometrial cancers but low in normal tissues, offers potential for a differentiated precision therapy. The responses observed across varying levels of B7-H...